Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep;56(5):903-904.
doi: 10.1111/apt.17136.

Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue

Lorenzo Bertani  1   2 , Domenico Tricò  3   4
Affiliations
Editorial

Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue

Lorenzo Bertani et al. Aliment Pharmacol Ther. 2022 Sep.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

References

REFERENCES

    1. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D’Haens G, Sandborn WJ, et al. The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for our patients? J Crohns Colitis. 2018;12(1):105-19.
    1. Xu G, Yan W, Li J. An update for the controversies and hypotheses of regulating nonthyroidal illness syndrome in chronic kidney diseases. Clin Exp Nephrol. 2014;18(6):837-43.
    1. Shizuma T. Concomitant thyroid disorders and inflammatory bowel disease: a literature review. Biomed Res Int. 2016;2016:5187061.
    1. Bertani L, Trico D, Pugliese D, Privitera G, Linsalata G, Zanzi F, et al. Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients. Aliment Pharmacol Ther. 2021;53:273-280.
    1. Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, et al. Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease? Aliment Pharmacol Ther. 2022;56:783-793.